We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Catalent Biologics Adds New Technology Platform

Catalent Biologics Adds New Technology Platform

Catalent Biologics Adds New Technology Platform

Catalent Biologics Adds New Technology Platform

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Catalent Biologics Adds New Technology Platform"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Catalent, Inc. has announced that it has signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. The platform has the potential to enable a consistent and cost-effective method to manufacture multiple recombinant antibodies or other recombinant proteins in a single batch culture.

Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs. Catalent will also be able to leverage its own proprietary GPEx® technology to help enable that development.

“Combination antibody therapies are becoming the treatment standard for many indications within oncology, immuno-oncology, and infectious diseases,” commented Mike Riley, Vice President/General Manager, Catalent Biologics.

He added, “This technology platform has the potential to allow production of multiple antibodies in a significantly more cost-effective manner. This can allow innovators to look to combinations earlier in clinical development, and could be the difference in a new treatment getting to patients.”

Excelimmune's antibody combination expression system is based on a key innovation: the use of stable pools of cells generated by multiple directed gene insertions, instead of clonal cell lines. This attribute contributes to a quick, stable, and flexible culture system for mixtures of cells producing different antibodies.

This technology has the potential to pave the way for more consistent, cost-effective production of antibody combinations, which will allow complex antibody therapeutics to gain greater accessibility to the clinic.